GSK plc (GSK) ORD GBP0.3125
31.00p
(2.14%)
- Add to watchlist
- Create an alert
- This stock can be held in a
31.00p
(2.14%)
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
31.00p
(2.14%)
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
Share news, reports & tips
-
GSK gepotidacin edges closer to landmark approval for gonorrhoea
11 August 2025 07:15
(Sharecast News) - Drugmaker GSK moved closer to expanding its antibiotic portfolio on Monday, after US regulators accepted its application to review gepotidacin as a potential oral treatment for gonorrhoea.
-
GSK and CureVac secure $740m payout in mRNA patent settlement
8 August 2025 07:36
(Sharecast News) - Drugmaker GSK said on Friday that it had reached a settlement, alongside CureVac, to resolve long-running patent litigation with BioNTech and Pfizer over mRNA-based COVID-19 vaccines.
-
London close: Stocks fall on Trump's latest tariffs, US jobs data
1 August 2025 17:37
(Sharecast News) - London stocks ended the week lower on Friday as investors reacted to a fresh wave of US tariffs and disappointing economic data from the United States.
-
London close: Stocks mixed on robust US data, earnings flurry
30 July 2025 17:15
(Sharecast News) - London equities ended Wednesday narrowly mixed as investors weighed stronger-than-expected US economic data against a wave of corporate earnings that failed to inspire.
-
GSK Q2 revenues grow, expects FY performance to be top end of guidance
30 July 2025 07:36
(Sharecast News) - Drugmaker GSK said on Wednesday that Q2 revenues had grown as a strong specialty medicines performance drove sales and core operating profit growth.
-
London close: Stocks reverse gains to finish lower
28 July 2025 17:16
(Sharecast News) - London stocks ended lower on Monday, erasing earlier gains as investors reassessed the weekend's trade agreement between the United States and the European Union.
-
GSK and Hengrui unveil development deal worth up to $12bn
28 July 2025 07:17
(Sharecast News) - GSK has entered into a partnership with Chinese pharmaceutical outfit Hengrui Pharma to jointly develop up to 12 medicines, in a deal that could be worth up to $12bn.
-
London close: FTSE finishes week just shy of 9,000
18 July 2025 17:51
(Sharecast News) - London stocks ended higher on Friday, supported by a positive shift in investor sentiment following US consumer confidence data.
-
FDA rejects overall benefit/risk profile of GSK's blood cancer drug dosage
18 July 2025 07:42
(Sharecast News) - Drugmaker GSK said on Friday that the US Food and Drug Administration's Oncologic Drugs Advisory Committee had voted against the overall benefit/risk profile of its...
-
US FDA approves new format of GSK's Shingrix
17 July 2025 09:21
(Sharecast News) - GSK announced on Thursday that it has received approval from the US Food and Drug Administration for a new prefilled syringe presentation of its shingles vaccine, Shingrix.
-
US FDA to review GSK bid to extend use of respiratory virus drug
14 July 2025 07:03
(Sharecast News) - GSK said the US Food and Drug Administration has accepted an application for review to extend the indication of its Arexvy respiratory syncytial virus vaccine to adults aged 18-49 who are...
-
EMA accepts marketing authorisation application for GSK's linerixibat
23 June 2025 11:07
(Sharecast News) - GSK said on Monday that the European Medicines Agency has accepted its marketing authorisation application for linerixibat, an investigational treatment for cholestatic pruritus in...
Company announcements Announcements
-
Transaction in Own Shares
20 August 2025 07:00
GSK
-
Director/PDMR Shareholding
19 August 2025 15:30
GSK
-
Transaction in Own Shares
19 August 2025 07:00
GSK
-
Transaction in Own Shares
18 August 2025 07:00
GSK
-
Transaction in Own Shares
15 August 2025 07:00
GSK
-
Transaction in Own Shares
14 August 2025 07:00
GSK
-
Transaction in Own Shares
13 August 2025 07:00
GSK
-
Director/PDMR Shareholding
12 August 2025 15:30
GSK
-
Transaction in Own Shares
12 August 2025 07:00
GSK
-
FDA to review gonorrhea indication for gepotidacin
11 August 2025 07:00
GSK
-
Transaction in Own Shares
11 August 2025 07:00
GSK
-
CureVac/BioNTech mRNA patent litigation settlement
8 August 2025 07:00
GSK
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see https://www.sharecast.com/newsfeedterms/index.html for our terms and conditions.
© Digital Look Ltd 1998-2025. All rights reserved.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.